Jonathan Mandelbaum

Vice President

2022 - Current

Senior Associate

2020 - 2022

Principal

2017 - 2020

-Lead and support all aspects of company building and operations including: deal sourcing, technical and business diligence, talent recruitment, contract negotiations, project management, budget oversight, corporate and business development, preparing and presenting board meeting materials

Associate

2015 - 2017

-Lead and support all aspects of company building including: deal sourcing, diligence, company operations -Company creation activities: Petra Pharma ($48M); Lodo Therapeutics ($17M); ApoGen, deal lead ($7M) -Source new deals by attending networking events, startup pitch competitions and conferences, relationship building with tech transfer officers and key faculty, scientific literature review -Perform diligence activities including: competitive landscape and market analyses, engaging KOLs, collaborating with pharma partners on diligence, building research plans and associated budgets and drafting investment memos -Support company operations including: sourcing key personnel, identifying and facilitating business development opportunities, project and CRO management, scientific oversight and preparing board meeting decks -Manage deal flow by logging and tracking all opportunities in a database, running weekly triage meetings, tracking action item progress by team; provide deal flow analytics to CEO for presentation to investors -Generate monthly dashboard updates of portfolio companies for CEO to share with board of directors

Scientist I

2013 - 2015

-Research scientific literature and current trends in oncology drug discovery and development to identify and propose novel drug targets to senior management -Collaborate with cross-functional team members, locally and globally, to develop experimental research plans and coordinate research activities in support of new target ideas -Summarize research and present findings at internal project team meetings to the senior management -Leading biology efforts for early-stage new target projects through validation towards go/no-go decision points -created "New Targets Working Group", aimed to bring together scientists working on new target projects in order to share ongoing project data, best practices and troubleshoot technical issues -Member of "Early Portfolio Group" tasked to propose, evaluate and prioritize new targets -Performing and managing triage, due diligence and legal activities associated with early-stage (preclinical through Phase I) business development opportunities, coordinating communications with external parties and attending face to face meetings with potential partners -Attend and contribute to roundtable discussions with invited academic speakers to discuss potential areas of collaboration -Scouting for new targets and technologies at scientific conferences

Postdoctoral Fellow

2011 - 2013

Investigating the role of autophagy in the pathogenesis and treatment of cancer. I am developing cell-based drug discovery tools for target validation and mechanism of action studies of a cancer metabolism target of interest within the autophagy pathway. I am additionally exploring potential biomarkers for predicting whether specific tumor subtypes are sensitive or resistant to autophagy inhibition.

Postdoctoral Fellow

2010 - 2011

Investigating the molecular and genetic pathogenesis of diffuse large B-cell lymphoma. Using a combination of genome-wide approaches, in vitro functional assays and in vivo mouse models, we are elucidating the role of recurrently mutated genes in the pathogenesis of DLBCL.

Graduate Research Assistant

2005 - 2010

Investigating the molecular and genetic pathogenesis of diffuse large B-cell lymphoma. Using a combination of genome-wide approaches, in vitro functional assays and in vivo mouse models, we are elucidating the role of recurrently mutated genes in the pathogenesis of DLBCL.